Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...
May 7, 2026 09:17 AM EDTUpdated 10:46 AM Cell/Gene TxFDA+ Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure Max Gelman Senior Editor There’s new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that